The CAR construct used in the GINAKIT2 study was also engineered to induce expression of the cytokine, IL-15. No significant treatment associated toxicities, including cytokine release syndrome or neurotoxicity, were observed.
There was also strong radiological evidence of extensive tumor regression at 4 weeks post infusion in one patient, with further regression observed at 8 weeks. Early data from the first two patients at the lowest dose level (3 x 106 CAR-NKT cells/m2) showed substantial in vivo expansion of CAR-NKT cells and subsequent infiltration of CAR-NKT cells into both the solid tumor mass and bone marrow. Patients were infused with an autologous CAR-NKT therapy, engineered to target GD2+ neuroblastoma cells.
BAYLOR COLLEGE OF MEDICINE HOSPITAL TREATED WHICH PATIENT TRIAL
GINAKIT2 Phase 1 trial is evaluating GD2 targeted CAR-NKT therapy, CMD-501, in children with relapsed or refractory (R/R) high risk neuroblastoma Cell Medica, a leader in next-generation cellular immunotherapies for the treatment of cancer, today announced that its collaborators from Baylor College of Medicine and Texas Children’s Hospital presented the latest positive progress in the GINAKIT2 trial for children with R/R high risk neuroblastoma at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, D.C.* Early data show highly innovative chimeric antigen receptor-natural killer T cell (CAR-NKT) therapy homing to and shrinking solid tumors in neuroblastoma patients